Finance

Beta
Lists
001067:KRX
JW Pharmaceutical(2Pb) Pref Shs
₩46,000.00
+0.88%
(+400.00) 1D
Jun 5, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 001067...
Open
₩44,800
High
₩46,000
Low
₩44,450
Mkt. cap
622.55B
Avg. vol.
73.00
Volume
89.00
Dividend
1.41%
Quarterly dividend
₩163
Ex-dividend date
Dec 27, 2024
P/E ratio
15.53
52-wk high
₩65,600
52-wk low
₩44,450
EPS
₩2,962
Shares outstanding
209.97K
No. of employees
1K
Open
₩44,800
High
₩46,000
Low
₩44,450
Mkt. cap
622.55B
Avg. vol.
73.00
Volume
89.00
Dividend
1.41%
Quarterly dividend
₩163
Ex-dividend date
Dec 27, 2024
P/E ratio
15.53
52-wk high
₩65,600
52-wk low
₩44,450
EPS
₩2,962
Shares outstanding
209.97K
No. of employees
1K
News stories
From sources across the web
About JW Pharmaceutical(2Pb) Pref Shs
CEOLee, Kyung Ha
Employees1.07K
Founded1945
Headquarters-
SectorPharmaceutical industry
Websitejw-pharma.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
191.10B
200.02B
198.94B
199.88B
Cost of goods sold
100.45B
105.39B
109.09B
101.43B
Cost of revenue
100.45B
105.39B
109.09B
101.43B
Research and development expenses
12.76B
7.33B
15.27B
9.38B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
53.14B
55.58B
60.42B
55.91B
Operating expense
65.69B
62.60B
80.98B
64.88B
Total operating expenses
166.14B
167.99B
190.07B
166.31B
Operating income
24.97B
32.03B
8.87B
33.58B
Other non operating income
-4.88B
-4.64B
8.03B
1.21B
EBT including unusual items
20.63B
27.85B
17.49B
35.20B
EBT excluding unusual items
20.63B
27.85B
15.96B
35.20B
Income tax expense
22.50B
-2.74B
2.18B
7.72B
Effective tax rate
109.04%
-9.83%
12.44%
21.93%
Other operating expenses
-
-
-
-
Net income
-1.87B
30.59B
15.32B
27.48B
Net profit margin
-0.98%
15.29%
7.70%
13.75%
Earnings per share
-
1.27K
-
-
Interest and investment income
-
-
3.34B
-
Interest expense
-
-
-4.42B
-
Net interest expenses
-
-
-1.09B
-
Depreciation and amortization charges
-
-
-
-
EBITDA
29.60B
36.72B
13.65B
38.56B
Gain or loss from assets sale
36.61M
5.12M
3.00K
-10.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer